全文获取类型
收费全文 | 887109篇 |
免费 | 73050篇 |
国内免费 | 1934篇 |
专业分类
耳鼻咽喉 | 13047篇 |
儿科学 | 25274篇 |
妇产科学 | 25691篇 |
基础医学 | 127326篇 |
口腔科学 | 26340篇 |
临床医学 | 78084篇 |
内科学 | 169559篇 |
皮肤病学 | 17334篇 |
神经病学 | 72433篇 |
特种医学 | 36221篇 |
外国民族医学 | 171篇 |
外科学 | 139149篇 |
综合类 | 24875篇 |
现状与发展 | 2篇 |
一般理论 | 294篇 |
预防医学 | 69548篇 |
眼科学 | 21170篇 |
药学 | 66804篇 |
中国医学 | 1630篇 |
肿瘤学 | 47141篇 |
出版年
2018年 | 7784篇 |
2015年 | 8170篇 |
2014年 | 11804篇 |
2013年 | 17961篇 |
2012年 | 24390篇 |
2011年 | 25650篇 |
2010年 | 14854篇 |
2009年 | 14056篇 |
2008年 | 24316篇 |
2007年 | 26545篇 |
2006年 | 26422篇 |
2005年 | 25989篇 |
2004年 | 25528篇 |
2003年 | 24534篇 |
2002年 | 23634篇 |
2001年 | 36068篇 |
2000年 | 36636篇 |
1999年 | 31164篇 |
1998年 | 9589篇 |
1997年 | 8852篇 |
1996年 | 8761篇 |
1995年 | 8262篇 |
1994年 | 7955篇 |
1992年 | 26799篇 |
1991年 | 26249篇 |
1990年 | 25733篇 |
1989年 | 24790篇 |
1988年 | 23325篇 |
1987年 | 22986篇 |
1986年 | 21830篇 |
1985年 | 21224篇 |
1984年 | 16573篇 |
1983年 | 14132篇 |
1982年 | 9061篇 |
1981年 | 8402篇 |
1980年 | 7863篇 |
1979年 | 16828篇 |
1978年 | 12196篇 |
1977年 | 10261篇 |
1976年 | 9396篇 |
1975年 | 10200篇 |
1974年 | 12697篇 |
1973年 | 12167篇 |
1972年 | 11558篇 |
1971年 | 10695篇 |
1970年 | 10232篇 |
1969年 | 9912篇 |
1968年 | 8906篇 |
1967年 | 8236篇 |
1966年 | 7655篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
51.
52.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
53.
54.
55.
56.
57.
58.
59.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
60.